SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.

Esophageal Squamous Cell Carcinomas Clinical Trial

Official title:
Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 Combined With Irinotecan in the Treatment of Recurrent and Metastatic Esophageal Squamous Cell Carcinoma

Status Recruiting

Clinical Trial Summary

This multi-center, open label Phase II clinical study is performed in patients with relapsed and metastatic esophageal squamous cell carcinoma progressed on prior PD-1/L1 antibody with or without chemotherapy. This study is investigating the safety and efficacy of SI-B001 at optimal combination dose with irinotecan in patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma
Carcinoma, Squamous Cell
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinomas

Clinical Trial Details

NCT number	NCT05022654
Study type	Interventional
Source	Sichuan Baili Pharmaceutical Co., Ltd.
Contact	Hai Zhu
Phone	+8613980051002
Email	zhuhai@baili-pharm.com
Status	Recruiting
Phase	Phase 2
Start date	December 13, 2021
Completion date	April 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02611700` - Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma	Phase 3
Not yet recruiting	`NCT05621707` - Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)	Phase 2
Recruiting	`NCT04741490` - Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After Surgery	N/A
Not yet recruiting	`NCT05103501` - Salvage Immunotherapy and Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant Chemoradiotherapy	Phase 2